Skip to main content
Clinical Trials/NCT03626233
NCT03626233
Recruiting
Not Applicable

Study of the Physiology of Pre-eclampsia and Vascular Intrauterine Growth Restriction With Constitution of a Biological Collection

Centre Hospitalier Intercommunal Creteil1 site in 1 country500 target enrollmentAugust 6, 2018
ConditionsPre-Eclampsia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pre-Eclampsia
Sponsor
Centre Hospitalier Intercommunal Creteil
Enrollment
500
Locations
1
Primary Endpoint
genomic analysis on placenta
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Preeclampsia and intrauterine growth retardation (IUGR) are serious and frequent pathologies, specific to pregnancy. They represent 70 000 new cases a year, or 9% of pregnancies and cause 50,000 premature births per year in France. The consequences in terms of morbidity and perinatal morbidity and the medical and economic costs make it an issue public health. Pre-eclampsia associates maternal hypertension with dysfunction kidney. There is no cure for pre-eclampsia or IUGR vascular during pregnancy. These pathologies invariably evolve towards a maternal and / or fetal aggravation sometimes very fast. Primary prevention and secondary education and screening for these pathologies are still insufficient. A better understanding of the pathophysiology of these placental vascular pathologies is necessary for the development of supported medical, obstetric and pediatric that will improve the state of health maternal and neonatal

Registry
clinicaltrials.gov
Start Date
August 6, 2018
End Date
April 2024
Last Updated
3 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • pregnant women
  • With or without vascular pathology

Exclusion Criteria

  • refusal to participate
  • multiple pregnancy
  • major fetal malformation diagnosed during pregnancy follow-up

Outcomes

Primary Outcomes

genomic analysis on placenta

Time Frame: day of delivery

by chromatin immunoprecipitation-sequencing (ChIP-seq)

Secondary Outcomes

  • genomic analysis on placenta(day of delivery)
  • PLGF blood level(day of delivery)
  • sFlt1 blood level(day of delivery)
  • genomic analysis on blood(day of delivery)
  • VEGF blood level(day of delivery)
  • sKDR blood level(day of delivery)

Study Sites (1)

Loading locations...

Similar Trials